White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
HOUSTON, April 26, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Deutsche Bank 42nd Annual Health Care Conference on Wednesday, May 3 at 2:10 p.m. EDT in Boston, Massachusetts.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles 646-513-3125 [email protected]
